A detailed history of Price T Rowe Associates Inc transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,841,502 shares of AUTL stock, worth $10.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,841,502
Previous 4,414,087 12.97%
Holding current value
$10.8 Million
Previous $15.4 Million 9.22%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.38 - $4.69 $1.94 Million - $2.69 Million
-572,585 Reduced 12.97%
3,841,502 $13.9 Million
Q2 2024

Aug 14, 2024

SELL
$3.33 - $5.68 $3.58 Million - $6.11 Million
-1,074,899 Reduced 19.58%
4,414,087 $15.4 Million
Q1 2024

May 15, 2024

BUY
$5.39 - $7.29 $13.4 Million - $18.1 Million
2,487,778 Added 82.89%
5,488,986 $35 Million
Q4 2023

Feb 14, 2024

BUY
$2.13 - $6.63 $6.39 Million - $19.9 Million
3,001,208 New
3,001,208 $19.3 Million

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $255M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.